Notice of first launch, interruption or termination of supply of a human drug
 Date ▲HolderCodeDrugDate fromSubject
 27.7.2023MEDOCHEMIE Ltd. (MOE)37101ARKETIS 20 mg (tbl 60x20 mg (blis.PVC/Al))26.7.2023O
 27.7.2023MEDOCHEMIE Ltd. (MOE)37109ARKETIS 30 mg (tbl 30x30 mg (blis.PVC/Al))26.7.2023O
 27.7.2023MEDOCHEMIE Ltd. (MOE)5243BAXETINE 500 mg (tbl flm 10x500 mg (blis.Al/Al))26.7.2023R
 27.7.2023MEDOCHEMIE Ltd. (MOE)53522RAMIMED 5 mg (tbl 30x5 mg (blis.Al/Al/PA/PVC))26.7.2023R
 27.7.2023MEDOCHEMIE Ltd. (MOE)7672BSAGILIA 1mg tablety (tbl 28x1 mg (blis.PVC/PE/PVDC/Al))26.7.2023R
 27.7.2023MEDOCHEMIE Ltd. (MOE)8859AMEDOSPIR 25 mg (tbl 100x25 mg (blis.PVC/Al))26.7.2023O
 27.7.2023GlaxoSmithKline Trading Services Limited (GAG-IRL-3)6360CAugmentin DUO s príchuťou miešaného ovocia (plu por 1x70 ml (fľ.skl.))20.7.2023O
 27.7.2023GlaxoSmithKline (Ireland) Limited (GAG-IE-2)18411Flixonase Aqueous Nasal Spray (aer nau 1x120 dávok (fľ.skl.s rozprašovačom))26.7.2023O
 27.7.2023GlaxoSmithKline Trading Services Limited (GAG-IRL-3)12494Augmentin 1 g (tbl flm 14x1 g (blis.Al/PVC/PVDC))20.7.2023O
 27.7.2023GlaxoSmithKline Trading Services Limited (GAG-IRL-3)62239Zinnat 125 mg/5 ml (gru por 1x100 ml (liek.skl.tmavá))6.7.2023O
 27.7.2023GlaxoSmithKline (Ireland) Limited (GAG-IE-2)09505Benlysta 400 mg prášok na infúzny koncentrát (plc ifc 1x400 mg (liek.inj.skl.))20.7.2023O
 26.7.2023Bayer, spol. s r.o. (BAY-SK-2)31895Iberogast (sol por 1x100 ml (fľ.skl.hnedá))31.7.2023R
 26.7.2023Bayer, spol. s r.o. (BAY-SK-2)31893Iberogast (sol por 1x20 ml (fľ.skl.hnedá))31.7.2023R
 26.7.2023Zentiva, k.s. (ZNT-1)2517DZetovar 10 mg/80 mg tablety (tbl 90x10 mg/80 mg (blis.OPA/Al/PVC))26.7.2023R
 26.7.2023Zentiva, k.s. (ZNT-1)34745Rispen 2 (tbl flm 50x2 mg (blis.PVC/PVDC/Al))26.7.2023R

Subject means:
U-Placement of medicine to Slovakian market, R-Discontinuation of medicine supply to Slovakian market,
O-Resumption of medicine supply to Slovakian market, Z-Cancelation of medicine supply to Slovakian market


Date from
From
To



 
Processed by the system MCR.Prerusenie (8.0)